As previously reported, HSBC upgraded Johnson & Johnson to Buy from Hold with a price target of $170, up from $169. The shares have retreated to three year lows despite fundamentals that are unchanged and headwinds that are well known, says the analyst, who sees “asymmetric risk and attractive upside” as well as diversity that limits material operational downside for J&J. While Talc litigation is an overhang, a resolution would be positive, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $175 from $181 at RBC Capital
- Johnson & Johnson price target lowered to $170 from $180 at BofA
- J&J report ‘not alarming’ for Legend Biotech, says H.C. Wainwright
- Johnson & Johnson says no change to M&A strategy
- Johnson & Johnson says ‘off to solid financial start’ in 2024
